PANACEABIO

Panacea Biotec Share Price

 

 

Invest in Panacea Biotec with 2.22X leverage

Invest with MTF

Performance

  • Low
  • ₹366
  • High
  • ₹374
  • 52 Week Low
  • ₹281
  • 52 Week High
  • ₹582
  • Open Price₹367
  • Previous Close₹363
  • Volume65,126
  • 50 DMA₹377.43
  • 100 DMA₹388.08
  • 200 DMA₹393.41

Investment Returns

  • Over 1 Month -14.28%
  • Over 3 Month -10.61%
  • Over 6 Month -9.49%
  • Over 1 Year -10.56%

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Invest Now

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -313.5
  • PEG Ratio
  • -6.2
  • Market Cap Cr
  • 2,270
  • P/B Ratio
  • 2.7
  • Average True Range
  • 20.51
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.76
  • RSI
  • 45.94
  • MFI
  • 43.69

Panacea Biotec Financials

Panacea Biotec Technicals

EMA & SMA

Current Price
₹370.60
+ 7.45 (2.05%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹373.08
  • 50 Day
  • ₹377.43
  • 100 Day
  • ₹388.08
  • 200 Day
  • ₹393.41

Resistance and Support

362.68 Pivot Speed
  • R3 379.27
  • R2 373.58
  • R1 368.37
  • S1 357.47
  • S2 351.78
  • S3 346.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Panacea Biotec is a biotechnology company specializing in research, development, and manufacturing of vaccines, pharmaceuticals, and biosimilars. It operates state-of-the-art facilities in India, serving global markets across North America, Europe, and emerging economies.

Panacea Biotec (Nse) has an operating revenue of Rs. 603.85 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of -1% needs improvement, ROE of -1% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-11 Quarterly Results
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results & Dividend
2025-02-14 Quarterly Results

Panacea Biotec F&O

Panacea Biotec Shareholding Pattern

72.48%
0%
1.36%
17.49%
8.67%

About Panacea Biotec

  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • Chairman & Managing Director
  • Dr. Rajesh Jain
  • ISIN
  • INE922B01023

Similar Stocks to Panacea Biotec

Panacea Biotec FAQs

Panacea Biotec share price is ₹370 As on 09 February, 2026 | 16:11

The Market Cap of Panacea Biotec is ₹2270 Cr As on 09 February, 2026 | 16:11

The P/E ratio of Panacea Biotec is -313.5 As on 09 February, 2026 | 16:11

The PB ratio of Panacea Biotec is 2.7 As on 09 February, 2026 | 16:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23